Multivariate analysis of prognostic factors in patients with endometrial cancer

International Journal of Gynecology and Obstetrics

Volumn 53, Issue 1, 1996, Pages 23-30

  Kodama, S ^a   Kase, H ^a   Tanaka, K ^a   Matsui, K ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b Kashiwazaki Pub Hlth Ctr N P   (Japan)

Author keywords

Endometrial cancer; Multivariate analysis; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ARTICLE; ASCITES FLUID CYTOLOGY; CANCER INVASION; ENDOMETRIUM CANCER; FEMALE; HUMAN; HYSTERECTOMY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; SURGICAL TECHNIQUE; UTERINE CERVIX CANCER;

EID: 0030005223     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/0020-7292(95)02643-6     Document Type: Article

References (26)

1. DiSaia PJ, Creasman WT. Adenocarcinoma of the uterus. In: DiSaia PJ, Creasman WT, editors. Clinical gynecologic oncology. St Louis, MO: Mosby, 1994: 156-193.
2. Creasman WT, Weed Jr FC. Carcinoma of the uterus (FIGO stages I and II): clinical features and management. In: Coppleson M, editor. Gynecologic oncology. New York: Churchill Livingstone, 1993: 775-789.
3. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread pattern of endometrial cancer. A Gynecologic Oncologic Group study. Cancer 1987; 60: 2035-2041.
4. Tornos C, Silva EG, El-Naggar A, Burk TW. Aggressive stage I grade 1 endometrial carcinoma. Cancer 1992; 70: 790-798.
5. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma. A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1981; 6: 93-108.
6. Connelly PJ, Alberhasky RC, Christopherson WM. Carcinoma of the endometrium. III. Analysis of 865 cases of adenocarcinoma and adenoacanthoma. Obstet Gynecol 1981; 59: 569-575.
7. Hanson MB, van Nagell R, Powell DE, Donaldson ES, Gallion H, Merhige M et al. The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer 1985; 55: 1753-1757.
8. Lee KR, Vacek P, Belinson JL. Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid adenocarcinoma. Gynecol Oncol 1994; 54: 10-18.
9. Ng AP, Reagan JW. Incidence and prognosis of endometrial carcinoma by histologic grade and extent. Obstet Gynecol 1970; 35: 437-443.
10. Piver MS, Lele SB, Barlow JJ, Blumenson L. Paraaortic lymph node evaluation in stage I endometrial carcinoma. Obstet Gynecol 1981; 59: 97-100.
11. Larson DM, Copeland LJ, Gallager HS, Wharton JT, Gershenson DM, Edwards CL et al. Prognostic factors in stage II endometrial carcinoma. Cancer 1987; 60: 1358-1361.
12. Christopherson WM, Connelly PJ, Alberhasky RC. Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and stage I disease. Cancer 1983; 51: 1705-1709.
13. Nielsen AL, Thomsen HK, Nyholm HCJ. Evaluation of the reproducibility of the revised 1988 International Federation of Gynecology and Obstetrics grading system of endometrial cancers with special emphasis on nuclear grading. Cancer 1991; 68: 2303-2309.
14. Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 1992; 46: 145-149.
15. Rosenberg P, Wingren S, Simonsen E, Stal O, Risberg B, Nordenskjöld B. Flow cytometric measurement of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator. Gynecol Oncol 1989; 35: 50-54.
16. Ambros RA, Kurman RJ. Identification of patients with stage I endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol Oncol 1992; 45: 235-239.
17. Creasman WT, Soper JT, McCarty KS, Hinslaw W, Clarke-Person DL. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 1985; 151: 922-932.
18. Geisiger KR, Homesley HD, Morgan TM, Kute TE, Marshall RB. Endometrial adenocarcinoma. A multiparameter clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors. Cancer 1986; 58: 1518-1525.
19. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley H et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncologic Group study. Gynecol Oncol 1991; 40: 55-65.
20. Ambros RA, Kurman RJ. Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. Cancer 1992; 69: 1424-1431.
21. Boente MP, Yordan Jr EL, McIntosh DG, Grendys Jr EC, Orandi YA, Davies S et al. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol 1993; 51: 316-322.
22. Creasman WT. Announcement, FIGO stages: 1988 reversions. Gynecol Oncol 1989; 3: 125-127.
23. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. WHO international histological classification of tumors. Uterine corpus. In: Histologic typing of female genital tumors. 2nd ed. New York: Springer-Verlag, 1994: 13-30.
24. Schutte B, Reynders MMJ, Bosman FT, Bliham GH. Flow cytometric determination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue. Cytometry 1985; 6: 26-30.
25. Truett J, Cornfield J, Kannel WB. Multivariate analysis of the risk for coronary heart disease in Framingham. J Chronic Dis 1967; 20: 511-524.
26. Burke TW, Gershenson DM, Morris M, Stringer CA, Levenback CL, Tortolero-Luna G, Barker W. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in woman with high-risk endometrial carcinoma. Gynecol Oncol 1994; 55: 47-50.